BCMA CAR T-cell therapy arrives for multiple myeloma: a reality

In the recent years, the development of immunotherapy has revolutionized the cancer treatment including multiple myeloma (MM). Therapeutic agents killing MM cells and activating immune cell function to overcome immunocompromised microenvironment further improved clinical outcome. Importantly, adoptive cellular therapy using chimeric antigen receptor (CAR) T cell targeting specifically expressed antigen on tumor cells has become one of the exciting breakthrough in MM immunotherapy.